ACTION OF THYROID HORMONES IN SORAFENIB TREATMENT OF THYROID CANCER

CAMPOS HAEDO MN; DÍAZ FLAQUÉ MC; STERLE HA; DÍAZ ALBUJA JA; PERONA M; JUVENAL GJ; CREMASCHI GA; ROSEMBLIT C

Mar del Plata

Congreso; REUNIÓN CONJUNTA SAIC SAI&FAIC SAFIS 2022; 2022

SAIC, SAI, SAFIS

Background. Thyroid carcinoma (TC) is the most common endocrine neoplasia. Its incidence has increased in the last 40 years worldwide. Sorafenib (Sor), a tyrosine kinase inhibitor, was approved for the treatment of TC, being hypothyroidism the most frequent consequence of Sor-induced endocrine dysfunction. We have described that thyroid hormones (TH) increase cell proliferation in TC lines. Thus, hormone replacement therapy to treat Sor-induced hypothyroidism could negatively affect the antitumor action. We have also shown that the selective inhibition of the TH membrane receptor, αVβ3 integrin, diminishes proliferation. Objective. To study integrin αVβ3 inhibition to enhance Sor antineoplastic activity in TC and the molecular mechanisms involved. Results. We first studied the role of αvβ3 integrin in Sor inhibition of TH-induced proliferation in TC cells. The treatment of the human anaplastic 8505C TC cells with the αvβ3 integrin antagonist Cilengitide (Cile) inhibits TH-induced proliferation by MTS assay (p